이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Eisai 관리

관리 기준 확인 1/4

Eisai's CEO는 Haruo Naito, Jun2003 에 임명되었습니다 의 임기는 21.08 년입니다. 는 ¥ 4.36B 가치에 해당하는 회사 주식의 0.23% 직접 소유합니다. 4.36B. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 3.1 년입니다.

주요 정보

Haruo Naito

최고 경영자

JP¥211.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	21.3yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	1.7yrs
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Haruo Naito 의 보수는 Eisai 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	JP¥33b
Mar 31 2024	JP¥211m	n/a	JP¥42b
Dec 31 2023	n/a	n/a	JP¥45b
Sep 30 2023	n/a	n/a	JP¥48b
Jun 30 2023	n/a	n/a	JP¥49b
Mar 31 2023	JP¥157m	n/a	JP¥55b
Dec 31 2022	n/a	n/a	JP¥27b
Sep 30 2022	n/a	n/a	JP¥32b
Jun 30 2022	n/a	n/a	JP¥33b
Mar 31 2022	JP¥127m	JP¥89m	JP¥48b
Dec 31 2021	n/a	n/a	JP¥57b
Sep 30 2021	n/a	n/a	JP¥63b
Jun 30 2021	n/a	n/a	JP¥60b
Mar 31 2021	JP¥125m	JP¥89m	JP¥42b
Dec 31 2020	n/a	n/a	JP¥94b
Sep 30 2020	n/a	n/a	JP¥121b
Jun 30 2020	n/a	n/a	JP¥125b
Mar 31 2020	JP¥157m	JP¥89m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥97b
Sep 30 2019	n/a	n/a	JP¥58b
Jun 30 2019	n/a	n/a	JP¥73b
Mar 31 2019	JP¥152m	JP¥89m	JP¥63b

보상 대 시장: Haruo 의 총 보상 ($USD 1.34M )은 JP 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.46M ).

보상과 수익: Haruo 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Haruo Naito (77 yo)

21.3yrs

테뉴어

JP¥211,000,000

보상

Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

리더십 팀

이름	위치	테뉴어	보상	소유권
Haruo Naito	CEO, Representative Corporate Officer & Director	21.3yrs	JP¥211.00m	0.23% ¥ 3.5b
Gary Hendler	Senior VP & President of EMEA Region	no data	JP¥218.00m	데이터 없음
Lynn D. Kramer	VP & Chief Clinical Officer	no data	JP¥297.00m	데이터 없음
Yanhui Feng	Senior Vice President	4.7yrs	JP¥189.00m	데이터 없음
Mitsuru Shomon	VP & CFO	1.2yrs	데이터 없음	데이터 없음
Keisuke Naito	Representative Corporate Officer	less than a year	데이터 없음	데이터 없음
Makoto Hoketsu	VP & Chief Information Officer	less than a year	데이터 없음	데이터 없음
Masatomi Akana	Senior VP	1.7yrs	데이터 없음	데이터 없음
Shin Kato	VP, General Counsel & Chief Compliance Officer	less than a year	데이터 없음	데이터 없음
Sayoko Sasaki	Vice President of Corporate Communications & Sustainability	2.7yrs	데이터 없음	데이터 없음
Teruyuki Masaka	VP, Chief HR Officer & Corporate Officer of General Affairs Japan Subsidiaries	2.7yrs	데이터 없음	데이터 없음
Takashi Owa	Senior VP & Chief Scientific Officer - Japan Medical Safety	no data	데이터 없음	데이터 없음

1.7yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: 4523 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Haruo Naito	CEO, Representative Corporate Officer & Director	10.3yrs	JP¥211.00m	0.23% ¥ 3.5b
Yuko Yasuda	Outside Independent Director	1.3yrs	데이터 없음	0.000020% ¥ 302.3k
Fumihiko Ike	Independent Outside Chairman	3.3yrs	데이터 없음	0.00035% ¥ 5.3m
Toru Moriyama	Outside Independent Director	1.3yrs	데이터 없음	0.00016% ¥ 2.4m
Kenta Takahashi	Director	less than a year	데이터 없음	0.0039% ¥ 58.9m
Ryota Miura	Independent Outside Director	3.3yrs	데이터 없음	0.00032% ¥ 4.8m
Hiroyuki Kato	Director	2.3yrs	데이터 없음	0.0030% ¥ 45.2m
Yoshiteru Kato	Director	3.3yrs	데이터 없음	0.0038% ¥ 57.1m
Yumiko Miwa	Independent Outside Director	4.3yrs	데이터 없음	0.00043% ¥ 6.5m
Richard Thornley	Outside Independent Director	2.3yrs	데이터 없음	데이터 없음
Takuji Kanai	Independent Outside Director	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 4523 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Eisai 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new directors

High number of new directors

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Recent updates

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of JP¥80.00 per share at 1.9% yield

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

New minor risk - Share price stability

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Consensus EPS estimates fall by 25%

Now 21% undervalued

Upcoming dividend of JP¥80.00 per share at 2.2% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

CEO 보상 분석

CEO